These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 7551841)

  • 1. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group.
    Abrams P; Schulman CC; Vaage S
    Br J Urol; 1995 Sep; 76(3):325-36. PubMed ID: 7551841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
    Chapple CR; Wyndaele JJ; Nordling J; Boeminghaus F; Ypma AF; Abrams P
    Eur Urol; 1996; 29(2):155-67. PubMed ID: 8647141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
    Schulman CC; Cortvriend J; Jonas U; Lock TM; Vaage S; Speakman MJ
    Eur Urol; 1996; 29(2):145-54. PubMed ID: 8647140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia).
    Abrams P; Speakman M; Stott M; Arkell D; Pocock R
    Br J Urol; 1997 Oct; 80(4):587-96. PubMed ID: 9352698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.
    Buzelin JM; Fonteyne E; Kontturi M; Witjes WP; Khan A
    Br J Urol; 1997 Oct; 80(4):597-605. PubMed ID: 9352699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamsulosin for benign prostatic hyperplasia.
    Wilt TJ; Mac Donald R; Rutks I
    Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WITHDRAWN: Tamsulosin for benign prostatic hyperplasia.
    Wilt TJ; Macdonald R; Rutks I
    Cochrane Database Syst Rev; 2011 Sep; 2011(9):CD002081. PubMed ID: 21901681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group.
    Lepor H
    Urology; 1998 Jun; 51(6):892-900. PubMed ID: 9609623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamsulosin in men with confirmed bladder outlet obstruction: a clinical and urodynamic analysis from a single centre in New Zealand.
    Arnold EP
    BJU Int; 2001 Jan; 87(1):24-30. PubMed ID: 11121988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
    Kawabe K; Yoshida M; Homma Y;
    BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group.
    Schulman CC; Cortvriend J; Jonas U; Lock TM; Vaage S; Speakman MJ
    Eur Urol; 1999 Dec; 36(6):609-20. PubMed ID: 10559616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group.
    Chapple CR; Baert L; Thind P; Höfner K; Khoe GS; Spångberg A
    Eur Urol; 1997; 32(4):462-70. PubMed ID: 9412807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia.
    Kirby RS
    BJU Int; 2003 Jan; 91(1):41-4. PubMed ID: 12614248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses.
    Lee E; Lee C
    Br J Urol; 1997 Oct; 80(4):606-11. PubMed ID: 9352700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamsulosin: an update of its role in the management of lower urinary tract symptoms.
    Lyseng-Williamson KA; Jarvis B; Wagstaff AJ
    Drugs; 2002; 62(1):135-67. PubMed ID: 11790159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of tamsulosin 0.4 mg in Asian patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia refractory to tamsulosin 0.2 mg: a randomized placebo controlled trial.
    Kim JJ; Han DH; Sung HH; Choo SH; Lee SW
    Int J Urol; 2014 Jul; 21(7):677-82. PubMed ID: 24725169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.